Simon Barry J. sold $197K of IBRX
Simon Barry J. sold 25,000 shares of ImmunityBio, Inc. (IBRX) at $7.88 ($0.20M total) on 2026-06-24 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the director’s open-market sale of 25,000 shares at $7.8763 on 2026-06-24, with holdings after the trade of 2,802,788 shares.
Market read
Traders may monitor insider activity for sentiment, but 10b5-1 plans generally limit the signal strength.
What to watch
The filing does not indicate whether other insiders or institutions are buying/selling, nor does it provide any new operational or clinical catalyst.
Background
This is an SEC Form 4 insider transaction disclosure for ImmunityBio, Inc. (IBRX).
Ticker impact
ImmunityBio director Simon Barry sold 25,000 shares in an open-market transaction for about $196,907 under a 10b5-1 plan.
Low near-term impact; any effect is likely sentiment-only and outweighed by broader fundamentals.
The filing is a Form 4 insider sale, but it explicitly states a pre-arranged 10b5-1 plan, which reduces interpretive value for timing/expectations.
Market effects
No sector read-through; this is company-specific insider transaction disclosure.
None indicated.
None indicated.
Counterpoint
Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.
Key entities
- issuerImmunityBio, Inc.
Company whose director executed a disclosed insider sale under a 10b5-1 plan.
- insiderSimon Barry J.
Director who sold 25,000 shares in an open-market transaction.
